Tags

Type your tag names separated by a space and hit enter

A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29.
Br J Pharmacol. 2020 11; 177(21):4942-4966.BJ

Abstract

In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.

Authors+Show Affiliations

Chair, Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), School of Life Sciences, University of Nottingham, Nottingham, UK.Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.Executive Committee, NC-IUPHAR, University of Cambridge, Cambridge, UK.Principal Investigator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.Curator, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.Database Developer, Guide to PHARMACOLOGY (GtoPdb), Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.First Vice-President and Chair of Immunopharmacology Section, International Union of Basic and Clinical Pharmacology (IUPHAR), Hebrew University of Jerusalem, Jerusalem, Israel.University of Cambridge, Cambridge, UK.Senior Curator, Guide to PHARMACOLOGY (GtoPdb), Executive Committee, NC-IUPHAR, Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK.Deanery of Biomedical Sciences, University of Edinburgh, Edinburgh, UK. TW2Informatics Ltd, Gothenburg, Sweden.Secretary-General, International Union of Basic and Clinical Pharmacology (IUPHAR) and Spedding Research Solutions SAS, Le Vesinet, France.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32358833

Citation

Alexander, Steve P H., et al. "A Rational Roadmap for SARS-CoV-2/COVID-19 Pharmacotherapeutic Research and Development: IUPHAR Review 29." British Journal of Pharmacology, vol. 177, no. 21, 2020, pp. 4942-4966.
Alexander SPH, Armstrong JF, Davenport AP, et al. A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. Br J Pharmacol. 2020;177(21):4942-4966.
Alexander, S. P. H., Armstrong, J. F., Davenport, A. P., Davies, J. A., Faccenda, E., Harding, S. D., Levi-Schaffer, F., Maguire, J. J., Pawson, A. J., Southan, C., & Spedding, M. (2020). A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. British Journal of Pharmacology, 177(21), 4942-4966. https://doi.org/10.1111/bph.15094
Alexander SPH, et al. A Rational Roadmap for SARS-CoV-2/COVID-19 Pharmacotherapeutic Research and Development: IUPHAR Review 29. Br J Pharmacol. 2020;177(21):4942-4966. PubMed PMID: 32358833.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A rational roadmap for SARS-CoV-2/COVID-19 pharmacotherapeutic research and development: IUPHAR Review 29. AU - Alexander,Steve P H, AU - Armstrong,Jane F, AU - Davenport,Anthony P, AU - Davies,Jamie A, AU - Faccenda,Elena, AU - Harding,Simon D, AU - Levi-Schaffer,Francesca, AU - Maguire,Janet J, AU - Pawson,Adam J, AU - Southan,Christopher, AU - Spedding,Michael, Y1 - 2020/07/19/ PY - 2020/04/11/received PY - 2020/04/27/revised PY - 2020/04/28/accepted PY - 2020/5/3/pubmed PY - 2020/10/28/medline PY - 2020/5/3/entrez SP - 4942 EP - 4966 JF - British journal of pharmacology JO - Br J Pharmacol VL - 177 IS - 21 N2 - In this review, we identify opportunities for drug discovery in the treatment of COVID-19 and, in so doing, provide a rational roadmap whereby pharmacology and pharmacologists can mitigate against the global pandemic. We assess the scope for targeting key host and viral targets in the mid-term, by first screening these targets against drugs already licensed, an agenda for drug repurposing, which should allow rapid translation to clinical trials. A simultaneous, multi-pronged approach using conventional drug discovery methods aimed at discovering novel chemical and biological means of targeting a short list of host and viral entities which should extend the arsenal of anti-SARS-CoV-2 agents. This longer term strategy would provide a deeper pool of drug choices for future-proofing against acquired drug resistance. Second, there will be further viral threats, which will inevitably evade existing vaccines. This will require a coherent therapeutic strategy which pharmacology and pharmacologists are best placed to provide. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc. SN - 1476-5381 UR - https://www.unboundmedicine.com/medline/citation/32358833/A_rational_roadmap_for_SARS_CoV_2/COVID_19_pharmacotherapeutic_research_and_development:_IUPHAR_Review_29_ L2 - https://doi.org/10.1111/bph.15094 DB - PRIME DP - Unbound Medicine ER -